Animas recently announced it has discontinued sales of its pumps in the United States and Canada and will close its pump business. As Animas’ partner-of-choice for this transition, our Medtronic team is ready to help. We know that when it comes to your diabetes management needs, it’s a very personal decision and our experienced team is here to support you through every step in the process.
Over the past 30 years, we have set out to transform diabetes care to enable greater freedom and better health through innovations across the care continuum, through advanced pump and CGM therapies, and comprehensive services like our StartRight Program and 24-hour Helpline that has served over 1.2 million people in more than 100 countries worldwide to date. In fact, our unparalleled service is the #1 reason our customers stay with us. Guided by our Medtronic Mission, we continually strive to address unmet needs through best-in-class solutions for people with diabetes around the world.
We make it easy for our customers to stay connected with us and others in the Diabetes Online Community. Through our social channels, we share helpful diabetes tips, stories and perspectives from the community as well as from our Medtronic team. We count on our robust online community to give us feedback and help shape the solutions we innovate to help transform diabetes care so we invite you to join the conversation and stay connected with us!
If you need pump supplies or customer support for your current Animas pump, you can continue to use the same methods you do today – nothing changes for now. As always, an Animas team member can be reached at 877-937-7867 (US) and 866-406-4844 (Canada).
If your pump warranty has expired, you’re at risk of going off therapy should something happen to your Animas pump. The Medtronic team is ready to help. Now may be the best time to purchase our latest technology if you’ve met your insurance deductible and your benefits reset in January, as this means little to no out of pocket cost for you.
US Residents - Our latest breakthrough technology the MiniMed™ 670G system is the first and only system that personalizes therapy and adjusts to your lifestyle. Featuring SmartGuard™ HCL technology and our most accurate sensor to date – the NEW Guardian™ Sensor 3 – this revolutionary system works overtime to keep your sugar levels in range to ensure you don’t have to. Customers like Nicky (pictured) have shared that they’re able to just trust the system and enjoy their life like they haven’t been able to in a very long time. Please call a member of the Medtronic team at 1-855-322-9568 or click here to explore your options. The MiniMed 670G system is approved for people with type 1 diabetes 14 years of age and older.
If your warranty expires on or after September 30, 2019, Animas has arranged the option for you to transition to a MiniMed 630G delivery system at no cost. We will start to offer this option to eligible customers starting in Spring 2018 to enable plenty of time for the transition. Customers who choose not to transition to a Medtronic pump under this program can continue to use their Animas pump and should be aware that effective September 30, 2019, Medtronic will not be able to supply Animas cartridges or customer support for Animas pumps, so you may want to consider alternative therapy options. If you do not wish to wait for your warranty to expire or for May 2018 to learn more about your options, Medtronic offers an in-warranty upgrade program called Switch2System. More info can be found here or by calling 1-855-322-9568
Important Safety Information: MiniMed™ 670G System
The Medtronic MiniMed 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G system includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.
WARNING: Medtronic performed an evaluation of the MiniMed 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.
Only use rapid acting U100 insulin with this system. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed 670G system has not been studied in pregnant women. For complete details, including product and important safety information concerning the system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library.
MiniMed is a registered trademark and SmartGuard is a trademark of Medtronic, MiniMed Inc.